These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 34120321)

  • 41. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott IC; Hider SL; Scott DL
    Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database.
    Jiang Y; Zhou L; Shen Y; Zhou Q; Ji Y; Zhu H
    J Affect Disord; 2024 Feb; 346():223-229. PubMed ID: 37956832
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system.
    Wei C; Yin W; Hu T; Zhang J; Dan H; Wu B
    Front Pharmacol; 2023; 14():1323240. PubMed ID: 38264533
    [No Abstract]   [Full Text] [Related]  

  • 44. Dropped head syndrome: a rare adverse drug reaction identified in the FDA adverse event reporting system and review of case reports in the literature.
    Liu X; Zhao X; He Y; Tang Y; Yan XL; Zhao B; Dai Y
    Expert Opin Drug Saf; 2022 Oct; 21(10):1329-1336. PubMed ID: 35315301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database.
    Shao Q; Xu Y; Li M; Chu X; Liu W
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1147-1156. PubMed ID: 34170370
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database.
    Yang H; Wan Z; Chen M; Zhang X; Cui W; Zhao B
    Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):217-223. PubMed ID: 37243615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database.
    Wang Y; Lin Y; Lin Q; Liang H; Cai W; Jiang D
    Sci Rep; 2023 Jul; 13(1):12257. PubMed ID: 37507539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.
    Yan Y; Wang L; Yuan Y; Xu J; Chen Y; Wu B
    Expert Opin Drug Saf; 2024 Jun; 23(6):771-776. PubMed ID: 37615268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
    Jedlowski PM; Jedlowski MF; Fazel MT
    Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring adverse events of Vilazodone: evidence from the FAERS database.
    Jiang Y; Qu Y; Du Z; Ou M; Shen Y; Zhou Q; Tian L; Zhu H
    BMC Psychiatry; 2024 May; 24(1):371. PubMed ID: 38755677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System.
    Yu Z; Zhu H; Chen H; Zhu L; Liao X
    J Pharm Pharm Sci; 2023; 26():11235. PubMed ID: 36942297
    [No Abstract]   [Full Text] [Related]  

  • 53. Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the literature.
    Raisch DW; Garg V; Arabyat R; Shen X; Edwards BJ; Miller FH; McKoy JM; Nardone B; West DP
    Expert Opin Drug Saf; 2014 Jan; 13(1):15-23. PubMed ID: 24053773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system.
    Lu W; Sun S; Wei J; Thai S; Li D; Tang H; Wang T; Sun L
    Int J Clin Pharm; 2020 Oct; 42(5):1364-1368. PubMed ID: 32951183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dental Disorders Reported to the FDA Adverse Event Reporting System in Association with Buprenorphine: An Analysis by Ingredient Composition and Route of Administration.
    Woods RH
    Curr Drug Saf; 2024; 19(2):261-267. PubMed ID: 37526182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse events of epidiolex: A real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.
    Zhou Q; Du Z; Qu K; Shen Y; Jiang Y; Zhu H; Zhang X
    Asian J Psychiatr; 2023 Dec; 90():103828. PubMed ID: 37949044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
    Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
    Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.
    Fujimoto M; Hosomi K; Takada M
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):259-66. PubMed ID: 24472404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
    Wen H; Lu C; Zhang M; Qi X
    Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.